At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C - An Observational Study in Israel (CITRINE STUDY)
In Brief
An observational study evaluating Ombitasvir/paritaprevir/ritonavir, Dasabuvir, and 2 other interventions for Chronic Hepatitis C. Completed, enrolled 256 participants across 18 sites.
Detailed Summary
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions. This observational study was the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in Israel in a clinical practice patient population.
Study Details
Timeline
Interventions
Co-formulated tablet
Tablet
Tablet
Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.